Search

Displaying results 5061 - 5070 of 10000 in total
  1. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting … RESP301 was also studied in a terminated trial (NCT05101915) for patients with mycobacterium abscesses and cystic fibrosis and in a completed trial with results (NCT04460183) for efficacy and safety in

  2. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B … cell malignancies including chronic lymphocytic leukemia), NCT05280509 (recruiting, combination with Ruxolitinib in myelofibrosis), NCT04655118 (recruiting, myelofibrosis), NCT04669067 (active, not recruiting

  3. Drug

    3-Methylfentanyl

    go.drugbank.com/drugs/DB01571
    ExperimentalIllicit

    times more potent than morphine in certain cases. 3-Methylfentanyl was initially discovered in 1974 and widespread illegal use of this drug has occurred since this time. … 3-Methylfentanyl is an opioid analgesic and is an analog of the potent opioid, fentanyl. 3-Methylfentanyl is one of the most powerful opioid drugs sold illegally and is estimated to be between 400-6000

  4. Drug

    Tolperisone

    go.drugbank.com/drugs/DB06264
    Investigational

    It possesses a high affinity for nervous system tissue, reaching highest concentrations in brain stem, spinal cord and peripheral nerves. … Tolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels.

  5. Drug

    Afelimomab

    go.drugbank.com/drugs/DB04956
    Experimental

    Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.

  6. Drug

    ACY001

    go.drugbank.com/drugs/DB06355
    Experimental

  7. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

  8. Drug

    Sapacitabine

    go.drugbank.com/drugs/DB06365
    Investigational

  9. Drug

    Methyl undecenoyl leucinate

    go.drugbank.com/drugs/DB11272
    Approved

    Methyl undecenoyl leucinate is an active ingredient in whitening creams. … It is an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of various melanogenic genes.

  10. Drug

    Mimopezil

    go.drugbank.com/drugs/DB05520
    Experimental

    Mimopezil is an acetylcholinesterase (AChE) inhibitor that has demonstrated potential use in the treatment of Alzheimer's disease. … Mimopezil is a pro-drug that is rapidly absorbed and converted into huperzine A.

    Synonyms: N-(2-Hydroxy-3-methoxy-5-chlorobenzylidene)huperzine A